Over the last three decades, various approaches have been pursued to increase the retention of an oral dosage form in the stomach, including floating drug delivery systems (FDDS), swelling and expanding systems, bioadhesive systems, modified shape systems, high-density systems and other delayed gastric emptying devices (1). FDDS are widely explored for gastroretention purposes and have a bulk density lower than gastric fluids and thus remain buoyant in the stomach without affecting the gastric emptying rate for a prolonged period of time. While the system is floating on gastric contents, the drug is released slowly at a desired rate from the system (1, 2).
tamine actions at all H 2 -receptors, but are mainly used clinically as inhibitors of gastric acid secretion (6) . Local availability of H 2 -antagonists in stomach has a greater clinical significance in treatment of peptic ulcer. Ranitidine (RT), a H 2 -antagonist, is widely prescribed in active duodenal ulcers, gastric ulcers and gastroesophageal reflux disease. A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 hours and frequent administration leads to plasma fluctuations; hence, a sustained release dosage form of ranitidine is desirable. The short biological half-life of the drug (~2.5-3 hours) also favors development of a sustained release, gastroretentive formulation (7, 8) .
In the present study, an attempt was made to develop a gastroretentive in situ gelling liquid formulation using ranitidine for local release in the stomach. Gastroretentive in situ gelling liquid formulations were formulated using different grades and concentrations of sodium alginate.
EXPERIMENTAL

Materials
Ranitidine (RT) was received as a gift sample from Torrent Pharmaceuticals Ltd (India). Low viscosity (0.25 Pa s), medium viscosity (6.5 Pa s) and high viscosity (14.0 Pa s) grades of sodium alginate (SA) were purchased from Sigma-Aldrich (USA). Calcium carbonate, sodium citrate and calcium chloride were purchased from S.D. Fine Chem. Ltd (India). All other chemicals used in the study were of analytical grade.
Methods
Preparation of in situ gelling solution. -SA solutions (0.5-1.0 %, m/V) were prepared in deionized water by heating to 60°C under continuous stirring (3). After cooling below 40°C, various concentrations of CaCO 3 and the drug were dispersed/dissolved under continuous stirring. A few formulations were prepared in deionized water previously containing 0.45 % (m/V) sodium citrate and 0.15 % (m/V) calcium chloride (Table I) . The resulting formulations were finally stored in amber coloured bottles until further use.
Viscosity of in situ gelling solutions. -The viscosity of formulations was determined by a Brookfield viscometer DV-III (Brookfield, USA) using spindle number 21 with cup and bob setting at 50 rpm (Table II) .
Floating behavior. -The buoyancy lag time and buoyancy duration of the formulations were determined in simulated gastric fluid (0.1 mol L -1 HCl, pH 1.2). The time in minutes taken by the formulation to emerge on the dissolution medium surface (buoyancy lag time) and buoyancy duration was noted.
Drug content. -Ten mL of the solution was added to 900 mL of simulated gastric fluid (0.1 mol L -1 HCl, pH 1.2) and stirred for 1 h on a magnetic stirrer. The solution was filtered, suitably diluted with simulated gastric fluid and the drug concentration was determined by using a UV-visible spectrophotometer a (UV-1601 Shimadzu, Japan) at 226 nm against a suitable blank solution.
In vitro release. -The release of ranitidine from the formulations was determined using a USP/24 dissolution test apparatus (Tab Machines, India) with a paddle stirrer at 50 rpm. The dissolution medium used was 900 mL of simulated gastric fluid (0.1 mol L -1 HCl, pH 1.2) and temperature was maintained at 37 ± 0.2°C. Ten mL of the formulation were placed into a Petri dish (4.5 cm i.d.) which was kept in the dissolution vessel and simulated gastric fluid was carefully added to the vessel avoiding any disturbance of the Petri dish. At each time interval, a precisely measured sample of the dissolution medium was pipetted out and replenished with fresh medium. Ranitidine concentration in the aliquot was determined spectrophotometrically. Each study was conducted in triplicate (9) .
Mechanism of drug release. -To analyze the mechanism of drug release from the formulations, the in vitro dissolution data were fitted to zero-order (F = kt), first-order (F = e -kt ), Higuchi (F = k t), and Korsmeyer and Peppas (F = kt n ) release models (10) (11) (12) , where F is the fraction of drug released (£ 60%), k is the release constant and t is time. The viscosity of the formulations increased with an increase in sodium alginate concentration (Table II) from 0.5-1 % (m/V) within each grade (low, medium and high viscosity grades). This phenomenon is a consequence of increasing chain interaction with an increase in polymer concentration. Calcium carbonate, which is the source of cations, increased the viscosity of the formulation. This change in viscosity is due to the proportional increase in the amount of dispersed calcium carbonate.
The buoyancy lag time varied with the formulation variables. Formulation F10 (SA 0.75 % m/V, CaCO 3 1.5 % m/V) exhibited the least buoyancy lag time (17 s) while formulation F17 (SA 0.50 % m/V, CaCO 3 1 % m/V) exhibited the highest lag time (318 s) ( Table  II) . The decrease in the buoyancy lag time of an formulation F10 can be attributed to the availability of an increased amount of CO 2 as the concentration of calcium carbonate was increased, being entrapped in the formed gel to give rapid buoyancy. Irrespective of formulation variables, buoyancy duration was > 24 hours. The buoyancy lag time in- creased with an increase in SA viscosity and concentration (1.0 > 0.75 > 0.5 % m/V). As the drug concentration was increased from 1-3 % m/V, the buoyancy lag time also increased from 35 to 318 seconds. It appears that with higher polymer content, excipients and drug, the bulk density of the gel increased, resulting in extension of the lag time from a few seconds to minutes.
In vitro drug release study was conducted on the formulations for a period of 8 hours during which the highest drug release of 96.5 ± 0.3 % (n = 3) was observed with formulation F1 (SA 0.5 % m/V, drug 1 % m/V) and the least drug release of 74.1 ± 0.1 % with F13 (SA 0.75 % m/V, drug 1 % m/V) during the 8 hour dissolution study. The influence of SA grades on in vitro drug release is shown in Figure 1 . As the viscosity of the SA used in the formulation was increased from low to high, a decrease in the amount of drug release was observed. The drug release from the formulations with highly viscous SA was slower compared to formulations with medium and low viscous SA. Figure 1 shows the cumulative percentage drug release from formulations containing different levels of sodium alginate. The drug release decreased with an increase in SA concentration in each grade. This can be explained by the fact that as the concentra- tion of polymer increases, more polymeric chains are available for crosslinking with the calcium ion. As the crosslinking increases, it forms a stronger gel, across which drug diffusion becomes difficult (13, 14) . Among the eight formulations studied (F1 to F8) using different grades of sodium alginate, formulations F2 (SA low viscous, 0.75 % m/V) and F4 (SA medium viscous, 0.5 % m/V) were selected for further studies based on their viscosity, floating behaviour and in vitro drug release. Calcium carbonate (0.5-1.0 % m/V) was used as a gas generating agent and a source of cations for gelation in the formulation. Calcium ions cause in situ gelation by interacting with sodium alginate during which carbon dioxide is entrapped within this gel matrix attributing to the gel buoyancy. The desired buoyancy (> 24 h) was achieved with calcium carbonate concentration of 0.5 % (m/V) while a concentration up to 1.5 % (m/V) provided sustained release of ranitidine (Fig. 2) . The drug release decreased as the concentration of calcium carbonate in the formulation was increased. This may be attributed to the fact that as the concentration of calcium ions increases, cross-linking also increases. Although formulations F2 and F10 contain the same proportion of low viscous sodium alginate (0.75 % m/V), they differed in the calcium carbonate concentration. It is likely that the entire carboxylic acid group is cross-linked by free Ca 2+ ions when added in a concentration of 1 % m/V (formulation F2). Therefore, addition of a higher proportion of Ca 2+ source in formulation F10 (1.5 % m/V) might not have altered the cross-linking density, which could be the reason for the observed not significant change in drug release from formulations F2 and F10.
Ranitidine was incorporated in three different concentrations (1, 2 and 3 % m/V) to evaluate the effect of drug loading on the release profile (Fig. 3 ). An initial burst release of~60 % was observed from the studied formulations This indicates that, except for the initial burst release which was due to the channeling effect of ranitidine, the drug release in the next 5 hours was significantly sustained (p < 0.05). As shown in Table III , the coefficient of determinations (R 2 ) for the zero-order model ranges from 0.7733 to 0.9497 and that for the Higuchi model ranges from 0.8701 to 0.9911, suggesting the square root of the Higuchi time model for drug release from dosage forms. The drug release was further analyzed by the Korsmeyer-Peppas model to define the mechanism of drug release; n values obtained were in the range of 0.15-0.42, which further confirms the drug release by the diffusion mechanism.
CONCLUSIONS
In the present study, various in situ liquid oral formulations of ranitidine were prepared. The study has shown that by modifying parameters like the initial drug loading, concentration of gas generating agent and polymer content, the release can be modulated to the desired rate. By observing various evaluation parameters for the studied formulations, it can be stated that incorporation of sodium citrate and calcium chloride in the formulations is required to control and sustain the drug release from in situ gel. 
